Snakebite is a medical emergency in many parts of the world, particularly in the temperate regions. According to 2007 World Health Organization (WHO) report, there are about 5 million
snakebite incidences resulting in 2.5 million envenoming, and 125,000 deaths occur annually. Most affected are the healthy individuals like children and farming populations with resource poor settings and away from health care centers in low-income countries of Africa, Asia and Latin America. In view of this, the WHO has declared
snakebite as an ignored health crisis and a tropical disease. Although the death rate has reduced markedly due to
anti-venom regiment, several limitations of it offer scope for better understanding of various ignored issues. Currently,
snakebite therapeutics facing plethora of scientific, technological and public health challenges, including secondary/long term complications that have not been given importance so far. Because of dearth of knowledge,
venom researchers and medical practitioners from affected countries worldwide should join together to accomplish this scenario. In view of this, the present review provides a broader perspective on the possible production and application of highly effective therapeutic master
anti-venom, designing master diagnostic kit and also to deal with the inefficacy of
anti-venom therapy against local manifestations and secondary complications of
snakebite. The review demands thorough understanding of
venom pharmacology, inculcating new strategies to handle and to enhance the efficacy of
snakebite management and urge the governing systems of affected countries to take steps to curtail accidental debilitation and death rate of healthy individuals due to
snakebite.